about
Novel targeted agents for the treatment of lung cancer in ChinaCrizotinib versus chemotherapy in advanced ALK-positive lung cancer.Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.First-line crizotinib versus chemotherapy in ALK-positive lung cancer.Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaBrain metastasis responding to gefitinib alone.Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer.A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.Data mining on DNA sequences of hepatitis B virus.CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer.INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancerGenetic alterations of lung adenocarcinoma in relation to smoking and ethnicity.Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLCIdentification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.Clear cell carcinoma of the lung revisited.Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neuralEpidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS).EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic surveyCorrelation and prognostic significance of beta-galactoside alpha-2,6-sialyltransferase and serum monosialylated alpha-fetoprotein in hepatocellular carcinoma.Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer.Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography.EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.Genotype-specific genomic markers associated with primary hepatomas, based on complete genomic sequencing of hepatitis B virus.Immediate Versus Delayed Treatment with EGFR Tyrosine Kinase Inhibitors after First-line Therapy in Advanced Non-small-cell Lung CANCEREpigenomic analysis of lung adenocarcinoma reveals novel DNA methylation patterns associated with smoking.Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm.EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009.Population-based differences in treatment outcome following anticancer drug therapies.
P50
Q26786580-6F57F6B3-F7FC-4BAB-8C08-C50522D818FDQ27852316-46C583E4-270C-4B4B-A39B-E7DDECA95B75Q27852408-6458D691-1EAE-4960-BDA2-2720E8751D3DQ27853101-D313D1F7-12FB-4D66-B9EC-987E37D350F0Q27853120-DA40806B-5E65-4F42-AC9E-C23A86E8FE04Q27853367-BE0D05BE-7900-478B-B454-A0DA8C698A11Q27860881-733514D1-D582-4646-9BCD-F6B22914330FQ30975955-BC4669F7-CAE0-4CE6-B391-0694D7A632B4Q31111305-D7F103E6-0FC9-4437-B35A-D8602B992F7FQ31160116-1BC8977A-01D9-471A-84A4-78EA21200CC5Q33367325-5AB284BB-756C-41D5-8004-38C10351704DQ33368982-B5B133FA-37DC-447C-8794-F4E94D8EE956Q33391857-30B7764F-0B29-4C07-8210-3FF22C3144D2Q33408501-76F525F9-AACC-4431-BE2E-ECD3619A1BADQ33521023-35A21AB9-DC64-4A24-B821-E6FF87846050Q33793090-C601F806-7903-4241-84B4-B1EA8E70F8C2Q33808203-9CAEF399-FF2B-4C7D-80C4-9E0508E8B2C5Q33913015-26DED0A2-2A7D-440D-B17D-70055A7FC64FQ34044082-5DCFEE87-61D3-415F-AD44-4F4429F22D27Q34208895-CADC48AB-9511-4B66-9D3A-4432E7B5F74EQ34311186-1F568D53-5AA1-4562-BC7A-F1CA7392A7F0Q34328665-BF472590-963B-4F7A-BDFE-5A74619723DFQ34458218-61DA71A2-8C93-4202-8CAC-B6D9CAAEBA98Q34623175-976F9168-311A-4122-A54A-9EBD05624845Q35074025-A14ABAA1-A30E-4341-8DBA-CB7D791B1E1EQ35126110-FE5D5C33-4B17-4645-9CB3-DB7DF6EEBD6BQ35165915-C7AE6B4F-4A25-40F2-B425-F05128ACA508Q35231286-FCE76815-447F-48C0-B10D-49C2756D92CAQ35591583-4D37F90D-EAD9-43E3-BEA9-DC4EAAE1C494Q35844619-7FC7A9E4-D992-4AF3-B39C-CA30F8C19E7EQ36102842-7C38FB70-9EC4-409D-9300-5CAAD58387FDQ36284547-AC210DB8-2243-4D6F-B7B6-8DBC1730FB8BQ36334253-CF110CC8-39D1-4F61-B82F-9AAD771D4884Q36498203-1B9860E9-F8F2-46FB-909D-8516B1D2A987Q36654677-8182DF5F-5774-48C1-95B9-EF17B7D69365Q37281397-53105F36-8E2E-44C5-851C-AAA27B4DCD2FQ37573653-1DF66D31-D287-4BBF-8C49-5B0C8C5A7C35Q37592893-A7E54109-B873-4005-83FC-E1D1707B81C2Q37625444-EF4D29F7-4268-409D-BA94-45511E6762C3Q37686610-6E706FF0-EBC1-4B11-BD42-4E3426133FFE
P50
description
researcher ORCID ID = 0000-0002-8251-0551
@en
wetenschapper
@nl
name
Tony Mok
@ast
Tony Mok
@en
Tony Mok
@es
Tony Mok
@nl
type
label
Tony Mok
@ast
Tony Mok
@en
Tony Mok
@es
Tony Mok
@nl
prefLabel
Tony Mok
@ast
Tony Mok
@en
Tony Mok
@es
Tony Mok
@nl
P31
P496
0000-0002-8251-0551